Searchable abstracts of presentations at key conferences in endocrinology

ea0005oc40 | Thyroid and Calcium | BES2003

Matrix metalloproteinase 13 (MMP13) mutation causes spondyloepimetaphyseal dysplasia (SEMD), Missouri variant

Kennedy A , Christie P , Harding B , Pannett A , Dearlove A , Whyte M , Thakker R

SEMDs are a heterogeneous group of skeletal disorders characterised by defective growth and modelling of the spine and long bones. Genetic defects in two inherited SEMDs have been identified and these involve abnormalities of the collagen type II gene located on chromosome 12q12-q13.2, and an ATP sulfurylase/APS kinase gene located on 10q23-34. These are not the cause of the Missouri variant (SEMDMO), which occurs as an autosomal dominant trait in a unique four-gene...

ea0003oc3 | Genetics: New Insights into Endocrine Disease | BES2002

A molecular deletional-insertion involving chromosomes Xq27 and 2p25 causes X-linked recessive hypoparathyroidism

Bowl M , Nesbit M , Harding B , Levy E , Schlessinger D , Whyte M , Thakker R

X-linked recessive hypoparathyroidism (XLHPT), due to congenital parathyroid agenesis, has been reported in two related kindreds from Missouri, USA. Affected individuals, who are males, suffer from epilepsy due to hypocalcaemia during infancy, whilst the females are normocalcaemic. Studies have mapped XLHPT to chromosome Xq27 and defined a 1.5 Mbp interval flanked centromerically by Factor IX and telomerically by DXS984. DNA sequence analysis of 4 candidate genes (proto-dbl, A...

ea0029oc8.1 | Bone | ICEECE2012

Hypophosphatasia: enzyme replacement therapy (ENB-0040) decreases TNSALP substrate accumulation and improves functional outcome in affected adolescents and adults

Kishnani P. , Rockman-Greenberg C. , Whyte M. , Weber T. , Mhanni A. , Madson K. , Reeves A. , Mack K. , Plotkin H. , Kreher N. , Landy H.

Hypophosphatasia (HPP), a heritable metabolic bone disease, results from low alkaline phosphatase (TNSALP) activity. Inorganic pyrophosphate (PPi), an inhibitor of mineralization, and pyridoxal 5′-phosphate (PLP), are substrates that accumulate in HPP. There is no approved therapy. ENB-0040, a bone-targeted, recombinant, human TNSALP improves skeletal mineralization in affected infants and children with HPP.Objective: Evaluate substrate levels and ...